Dako signs collaboration agreement with Bristol-Myers Squibb for pharmacodiagnostics tests
Mon. June 30, 2008; Posted: 05:35 AM
Jun 30, 2008 (M2 EQUITYBITES via COMTEX) --
BMY |
Quote |
Chart |
News |
PowerRating -- Dako, a provider of cancer diagnostic solutions, said on 27 June that
the company has entered into a collaboration with Bristol-Myers Squibb
Company (NYSE:BMY) to develop pharmacodiagnostic tests intended to
identify patients more likely to benefit from treatment with certain
investigational cancer drug candidates under development by
Bristol-Myers Squibb.
The companies stated that pharmacodiagnostics are increasing in demand
as personalised medicine may provide a way to improve patient care and
manage healthcare costs by targeting treatments to individuals more
likely to benefit from specific therapies.
The new collaboration positions Dako in the clinical diagnostics market
and recognises the company as a strong partner for developing
diagnostic tests for use in conjunction with drug therapies.
Comments on this story may be sent to admin@m2.com
For full details on Bristol-Myers Squibb Co (BMY)
click here. Bristol-Myers Squibb Co (BMY) has Short Term PowerRatings of 4. Details on Bristol-Myers Squibb Co (BMY) Short Term PowerRatings is available at
This Link.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
